| Project/Area Number |
26461198
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
Kagawa Shizuko 慶應義塾大学, 医学部(信濃町), 研究員 (80645507)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
Fukunaga Koichi 慶應義塾大学, 医学部, 専任講師 (60327517)
Suzuki Yusuke 慶應義塾大学, 医学部, 特任講師 (80306696)
Kubo Akiharu 慶應義塾大学, 医学部, 専任講師 (70335256)
|
|---|
| Research Collaborator |
Kabata Hiroki
Masaki Katsunori
Mochimaru Takao
Matsusaka Masako
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 経皮感作 / 皮膚バリア / IL-23 / 気管支喘息 / 気道過敏性 / 好酸球 / 動物モデル / Th17 |
|---|
| Outline of Final Research Achievements |
Th17 cells are the main cells that produce IL-17A.We found that IL-23 is required for the differentiation of Th17 cells via a patch application on the skin.In oder to find a therapeutic target of percutaneous sensitized asthma, I focused on the role of IL-23 produced in the local skin region and the role of Th17 in cytokine enhancement by administrating anti-IL-23 or control IgG to a percutaneously sensitized asthma mouse model, and then evaluating it for eosinophilic airway inflammation In the group to which the anti-IL-23 antibody was administered during the sensitization phase, the production of OVA-specific IgG1 antibody tended to decrease compared to the group to which the control IgG antibody was administered, and furthermore, the bronchoalveolar lavage fluid eosinophil count and eosinophil infiltration in tissues were found to decrease significantly.
|
